Please assess the completion status of the following clinical trial:

Trial Title: Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Clinical stage I/II melanoma patients, planned to undergo a sentinel lymph node biopsy (SNB)~* ECOG performance status 0 or 1~* White blood count (WBC) ≥ 3 x10\^9/L~* Platelet count ≥ 100 x10\^9/L~* Hemoglobin ≥ 6.5 mmol/L~* Serum creatinine ≤ 2.5 x ULN~* Total serum bilirubin, AST, ALT and LDH ≤ 2x ULN~Exclusion Criteria:~* Non-oncology vaccine therapy used for prevention of infectious diseases (up-to) 4 weeks prior and/r 8 weeks after any dose of tremelimumab~* Prior treatment with a CD137 agonist or CTLA-4 inhibitor or agonist~* Uncontrolled infectious disease including negative testing for HIV, HBV, HCV~* Autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tremelimumab (Type: EXPERIMENTAL): Intradermal injection of tremelimumab at the primary melanoma excision site, 7 days prior to sentinel node biopsy (SNB), with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).

Based on this trial design, predict the completion outcome and termination type (if applicable).